Candriam S.C.A. Travere Therapeutics, Inc. Transaction History
Candriam S.C.A.
- $15.6 Billion
- Q1 2025
A detailed history of Candriam S.C.A. transactions in Travere Therapeutics, Inc. stock. As of the latest transaction made, Candriam S.C.A. holds 534,072 shares of TVTX stock, worth $11.4 Million. This represents 0.06% of its overall portfolio holdings.
Number of Shares
534,072Holding current value
$11.4 Million% of portfolio
0.06%Shares
1 transactions
Others Institutions Holding TVTX
# of Institutions
224Shares Held
94.1MCall Options Held
1.62MPut Options Held
774K-
Black Rock Inc. New York, NY7.64MShares$164 Million0.0% of portfolio
-
Armistice Capital, LLC New York, NY7.36MShares$158 Million1.81% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.01MShares$107 Million0.0% of portfolio
-
Rock Springs Capital Management LP Baltimore, MD4.97MShares$106 Million3.46% of portfolio
-
Macquarie Group LTD Australia, C34.26MShares$91.2 Million0.09% of portfolio
About Travere Therapeutics, Inc.
- Ticker TVTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 64,173,600
- Market Cap $1.37B
- Description
- Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic a...